KNSA KINIKSA PHARMACEUTICALS INTERNATIONAL PLC Disposals and divestitures 8-K Filing 2025 - License Termination Kiniksa Pharmaceuticals announced the termination of its license agreement with MedImmune for mavrilimumab effective May 22, 2025, and reported financial results for the year ending December 31, 2024, along with a plan to discontinue a clinical trial for abiprubart, incurring approximately $19 million in expenses and expecting an additional $14 million to $17 million in costs.Get access to all SEC 8-K filings of the KINIKSA PHARMACEUTICALS INTERNATIONAL PLC